ChinaBio Today submits: China Pharma Holdings (CPHI.OB) obtained approval from the SFDA to begin Phase I and Phase II clinical trials of Rosuvastatin, a generic version of the cholesterol-lowering statin drug Crestor. The trials will test the compound for efficacy. China Pharma will move to begin the trials immediately with the goal of winning approval by the end of …

More: continued here